Teleflex (TFX) Q4 2025 earnings review
Strategic Overhaul Secures Growth but Stranded Costs Decimate 2026 Earnings
Teleflex finalized a massive corporate transformation in Q4, formally moving its Acute Care, Interventional Urology, and OEM businesses into discontinued operations ahead of their sale. While the newly formed 'RemainCo' delivered a stable 4.3% pro forma constant currency revenue growth in Q4, the transition is taking a heavy toll on the bottom line. Adjusted operating margins collapsed by 440 basis points year-over-year to 21.5%, and 2026 guidance came in surprisingly weak. Management projects adjusted EPS to decline to a midpoint of $6.40 (down ~8% from $6.98 in 2025) as $90 million in 'stranded costs' offset the top-line gains. 2026 is strictly a transition year, heavily reliant on execution and future Transition Services Agreements to rebuild profitability in 2027.
🐂 Bull Case
By divesting the dragging Interventional Urology (UroLift) and OEM segments, Teleflex's 'RemainCo' is now a pure-play, mid-single-digit grower. The acquired BIOTRONIK Vascular Intervention business is performing well, driving 8.2% pro forma CC growth in the Interventional segment.
The strategic divestitures are expected to close in H2 2026, generating ~$1.8B in after-tax proceeds. Management plans to deploy this aggressively: $1 billion for share repurchases and $800 million for debt paydown, structurally improving 2027 EPS.
🐻 Bear Case
Investors must swallow an 8%+ decline in adjusted EPS for 2026 ($6.25-$6.55) due to $90M in stranded costs. The expected Transition Services (TS) and Manufacturing Services (MS) agreements to offset this will not materialize until after the deal closes in H2 2026.
The core Surgical segment reversed from +7.5% growth in Q3 to a -0.7% contraction in Q4, signaling that underlying base business challenges (such as China Volume-Based Procurement) still pose risks to the new RemainCo.
⚖️ Verdict: ⚪
Neutral. The long-term strategic pivot makes sense, ridding the company of its most problematic segments. However, the sheer mechanical complexity of the separation, the massive near-term margin hit, and a 'lost' earnings year in 2026 means investors must have extreme patience to see the normalized 2027 profile.
Key Themes
Stranded Costs Crush 2026 Operating Leverage
The mechanics of the divestiture are creating a severe near-term margin trough. Teleflex will carry $90 million in stranded operating costs throughout 2026 to support the transitioning businesses. This single factor pushes the forecasted 2026 adjusted operating margin down to ~19.0%, a steep drop from 22.7% in 2025. While management expects Transition Services (TS) and Manufacturing Services (MS) revenues to offset this post-close, those benefits are explicitly excluded from 2026 guidance, meaning the reported earnings will look highly compressed for the next 12 months.
Interventional Segment Thrives Post-Acquisition
The BIOTRONIK Vascular Intervention (VI) acquisition has successfully integrated into the continuing operations, turning the Interventional category into Teleflex's primary growth engine. The segment reported 8.2% pro forma constant currency growth in Q4 (and 8.1% for H2 2025). This validates management's strategy to build a $800M+ global franchise centered around the cath lab, offsetting historic weaknesses in other portfolios.
Surgical Segment Reversing to Negative Growth
Despite management's claim of creating a more focused and reliable 'RemainCo,' the Surgical product category showed a troubling reversal. Pro forma adjusted CC growth plummeted from +7.5% in Q3 to -0.7% in Q4. Management attributed this to the expected impact of volume-based procurement (VBP) in China, but a negative print in a core continuing operation contradicts the mid-single-digit stability narrative.
Restructuring Plan to Support Long-Term Margin Base
To eventually eliminate the stranded costs, the Board approved a multi-year restructuring plan aimed at right-sizing the global organization and supply chain. Teleflex expects to generate $48 million to $52 million in annual pre-tax savings by mid-2028. This provides a tangible bridge to rebuilding the operating margin back toward historical levels once the TS/MS agreements expire.
Macro: Tariffs and Cost Inflation Continue to Weigh
Underlying gross margin pressure remains a stubborn headwind. Q4 Adjusted Gross Margin for continuing operations contracted heavily to 62.8% from 65.8% a year ago. Management cited the negative impact of tariffs, higher logistics/distribution costs, and the dilutive gross margin profile of the newly acquired BIOTRONIK business compared to the corporate average.
Other KPIs
Decelerating significantly. Down 300 basis points from 65.8% in Q4 2024. The combination of structural changes (BIOTRONIK mix), ongoing tariff impacts, and foreign exchange continues to pressure the core profitability of the products.
A massive write-down reflecting the reclassification of Acute Care, Interventional Urology (UroLift), and OEM into discontinued operations. This effectively wipes out the historical drag of these segments, resetting the baseline for RemainCo.
Surged 31% from $306.8 million at the end of 2024. While part of this is the BIOTRONIK acquisition integration, elevated working capital during a period of complex separation poses a risk to free cash flow conversion.
Guidance
Stable. This guidance aligns perfectly with the 4.7% pro forma CC growth achieved in H2 2025. It suggests that the underlying 'RemainCo' portfolio can reliably deliver mid-single-digit volume expansion without the drag of the divested segments.
Reversing. The midpoint of $6.40 represents an 8.3% decline from the $6.98 achieved in 2025. This deceleration is entirely driven by the $90M in stranded costs and the delayed onset of offsetting TS/MS agreements. This establishes 2026 as an explicit earnings trough.
Decelerating. A stark drop from the 22.7% adjusted operating margin achieved in 2025. This metric visualizes the severe operational deleverage caused by keeping corporate infrastructure intact for a much smaller 'RemainCo' revenue base.
Key Questions
Surgical Segment Decline Details
Pro forma CC growth in the Surgical segment swung from +7.5% in Q3 to -0.7% in Q4. How much of this is strictly related to timing of VBP implementation in China versus underlying procedure volume softness in other regions?
Visibility into TS/MS Agreements
You are guiding to $90M in stranded costs but noted TS/MS agreements will fully offset this on an annualized basis post-close. Have the pricing and structures of these agreements already been contractually locked in with the buyer, or are they still subject to negotiation?
Gross Margin Stabilization
Adjusted gross margin compressed by 300 basis points in Q4. With the BIOTRONIK integration largely complete and the 2026 stranded costs primarily hitting OpEx, when should investors expect gross margins to stabilize or expand?